<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/98E9F3C0-31F7-4736-B420-F657D21DDA35"><gtr:id>98E9F3C0-31F7-4736-B420-F657D21DDA35</gtr:id><gtr:firstName>Sakari</gtr:firstName><gtr:surname>Vanharanata</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12022%2F7"><gtr:id>D5FCE2D2-96B3-4B8A-943B-E8FF8AF2216E</gtr:id><gtr:title>Molecular origins of metastatic cancer phenotypes</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12022/7</gtr:grantReference><gtr:abstractText>The spread of cancer to distant organs in a process termed metastasis is one of the most devastating aspects of cancer, being the cause of ~90% of cancer-related deaths. The vast majority of metastatic cancers are refractory to treatment and are therefore incurable. Thus, there is a pressing clinical need for further research on the molecular basis of metastatic cancer. Our approach combines state-of-the-art experimental cancer models, functional genetics and computer-based analysis of cancer data sets to identify genetic factors that are required for the growth and maintenance of metastatic cancer. The expected benefit from this work is a better understanding of the molecular mechanism that drive cancer metastasis. This knowledge will serve as a basis for the development of rational therapeutic strategies to combat metastatic cancer. Thus, the potential secondary benefits of this work will go beyond basic cancer research, possibly leading to the identification of (i) new molecular targets for metastatic cancer and (ii) novel predictive and/or prognostic biomarkers for metastatic cancer.</gtr:abstractText><gtr:technicalSummary>Metastatic dissemination remains one of the most devastating complications of cancer. In the clinic, metastases often present as the final step of disease progression, but the molecular origins of metastases may be rooted in the early steps of carcinogenesis. Several lines of evidence suggest that instead of specific mutations, metastatic phenotypes can emerge from optimized output of the oncogenic pathways that drive tumour initiation and early progression. The molecular mechanisms as well as phenotypic consequences of such optimization of pathway output remain elusive. Yet, understanding how metastatic cancer phenotypes arise and persist, to what extent this is dependent on the pathways that drive tumour initiation and early progression, and what genetic vulnerabilities advanced cancer clones have could profoundly affect our ability to fight metastatic cancer.
Using an integrative approach combining experimental cancer models, high-throughput genomics, functional genetics, bioinformatics and clinical association analysis, this programme aims at identifying genetic dependencies in metastatic cancer. With a focus on VHL mutant renal cancer, we will explore molecular mechanisms that modulate the phenotypic output of tumour-initiating mutations in support of metastasis, and test the hypothesis that this optimisation of oncogenic signalling results in molecular vulnerabilities in the most aggressive cancer clones. Understanding the origins of metastatic cancer phenotypes will provide insights into the fundamental requirements of cancer cell states and help identify functionally relevant biomarkers as well as therapeutic targets. Knowledge of the molecular networks that bolster the output of tumour-initiating genetic pathways in cancer progression may also have implications for early intervention strategies for cancer.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1571000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Participation in MRC Festival of Science Open Day at MRC CU</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DB36D294-0806-4A05-9E5E-553D72068CBA</gtr:id><gtr:impact>60 sixth-form students from across 8 schools in Cambridge visited the MRC Cancer Unit on the afternoon of the 22nd of June, 2016 for an Open Day. All students, accompanied by their teachers, were given a tour of the enitre building with an opportunity for engaging with researchers about the state of the art in cancer research and gaining hands-on experience with setting up experiments. Talks about career opportunities and challenges associated with pursuing cancer research were also available to all attendees. The event sparked a great deal of interest and enthusiasm in students and teachers alike and we have had a request for this event to be continued. We will be pursuing a similar format of activities for the MRC Science Festival in 2017, but reach out to more number of schools, including those outside of Cambridge city perimeters.</gtr:impact><gtr:outcomeId>589858d1f1e1c9.87061777</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>https://mrccancerunit.wordpress.com/2016/07/06/inspiring-the-next-generation-of-cancer-researchers-the-mrc-cancer-unit-open-day-2016/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>2)	Participation in Cambridge University Science Festival (2015-2016)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D67CAD99-A383-43DF-8779-2BDCE0E7A99F</gtr:id><gtr:impact>The Cambridge Science Festival aims to reach out to the general public and communicate about the different aspects of science and research being undertaken at the University. It is a free event, over two weeks, with an excess of 270 events and more than 30000 attendees. As part of this, the MRC CU along with the CRUK CI organised a set of talks and activities that were attended by over 100 people from all walks of life - from young children and young adults to parents/carers and professionals. The Vanharanta lab was part of the MRC CU team at this event. The event generated a lot of interest in cancer research, helped raise awareness about the importance of 'early' in cancer which is the mission of the MRC CU and also led to a lot of interest being generated in the MRC Festival of Science which followed on later in the year.</gtr:impact><gtr:outcomeId>589dd87bf025f9.79076200</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015,2016,2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>27000</gtr:amountPounds><gtr:country>Malaysia</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Scholarship</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>The National University of Malaysia (MUM)</gtr:fundingOrg><gtr:id>67F0AFD4-940C-4DAF-9D33-556DDF1E065A</gtr:id><gtr:outcomeId>55894fd5581fa7.68882716</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>27000</gtr:amountPounds><gtr:country>Malaysia</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Scholarship</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Majlis Amanah Rakyat (MARA)</gtr:fundingOrg><gtr:id>19AA1321-318C-40FC-BEC8-E5444C0E6536</gtr:id><gtr:outcomeId>5589505d9ed503.77894604</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>53B19534-DD34-4C23-994F-5C9052B7DC9C</gtr:id><gtr:title>Therapy-induced tumour secretomes promote resistance and tumour progression.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0890802f97fa062664e06e9d0f2c1afc"><gtr:id>0890802f97fa062664e06e9d0f2c1afc</gtr:id><gtr:otherNames>Obenauf AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>55894d5bc1b197.57768163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1C4E6EA-A330-4BA4-9D1F-17D22B415581</gtr:id><gtr:title>Origins of metastatic traits.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0866d6361eb6e8418f2796b21aa44c5a"><gtr:id>0866d6361eb6e8418f2796b21aa44c5a</gtr:id><gtr:otherNames>Vanharanta S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>545f4cbeb58f25.88881509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D1DA546-1946-48B2-823A-793192D1D8DD</gtr:id><gtr:title>Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dbaaf69c9396f6052964f9c61c02d07"><gtr:id>7dbaaf69c9396f6052964f9c61c02d07</gtr:id><gtr:otherNames>Jacob LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>561291d416d215.76890672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>718BE0B8-91D8-4A70-B4F9-E0BECAE82F10</gtr:id><gtr:title>Epigenetic determinants of metastasis.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39833713c73f56f451c0919ecff78a83"><gtr:id>39833713c73f56f451c0919ecff78a83</gtr:id><gtr:otherNames>Patel SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>58945f78314715.24427795</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A18667A5-A0F1-43B8-8816-04D56622C1DF</gtr:id><gtr:title>A hypoxic ticket to the bone metastatic niche.</gtr:title><gtr:parentPublicationTitle>Breast cancer research : BCR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0866d6361eb6e8418f2796b21aa44c5a"><gtr:id>0866d6361eb6e8418f2796b21aa44c5a</gtr:id><gtr:otherNames>Vanharanta S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1465-5411</gtr:issn><gtr:outcomeId>561291d4481053.98977797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F21FCC8-018B-4927-8BB1-B12A457FE7CC</gtr:id><gtr:title>Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b998be4188d5c8d563cef6a1110d03e9"><gtr:id>b998be4188d5c8d563cef6a1110d03e9</gtr:id><gtr:otherNames>Al-Lamki RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58945f780a8ab6.94942677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BC752FB-4C32-43D5-B950-7FEC04E1CA89</gtr:id><gtr:title>Hypoxia signaling--license to metastasize.</gtr:title><gtr:parentPublicationTitle>Cancer discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0866d6361eb6e8418f2796b21aa44c5a"><gtr:id>0866d6361eb6e8418f2796b21aa44c5a</gtr:id><gtr:otherNames>Vanharanta S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2159-8274</gtr:issn><gtr:outcomeId>545f4cbe8cab61.15876202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>808B2F61-2260-42A9-89F4-DF6F05CF1E15</gtr:id><gtr:title>Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0866d6361eb6e8418f2796b21aa44c5a"><gtr:id>0866d6361eb6e8418f2796b21aa44c5a</gtr:id><gtr:otherNames>Vanharanta S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>545f4cbedc0cf3.84678471</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12022/7</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>